Spring Bank Pharmaceuticals, Gilead Sciences and HBV
If Spring Bank Pharmaceuticals’ (SBPH) product inarigivir in combination with Gilead Sciences’ (GILD) Vemlidy® could validate the current encouraging results of the ongoing trials on chronic hepatitis B virus (HBV) infection, then the small underestimated firm would hand the giant biotech firm a valuable gift that could increase its sales revenues of its liver disease franchise.
Spring Bank Pharmaceuticals announced encouraging results from its product inarigivir when combined with Gilead Sciences’ product Vemlidy® (tenofovir alafenamide 25mg) for the treatment of chronic HBV infection.
In the Phase 2 trial 30 patients with the HBV infection received low-dose inarigivir 50mg plus Vemlidy® for 12 weeks and 12 patients with the HBV infection received Vemlidy® alone for 12 weeks.
Inarigivir plus Vemlidy® Results
- Interim top-line results from the first cohort indicate that, at week 12, 7 out of 30 patients on the small dose inarigivir 50mg plus Vemlidy® arm were hepatitis B surface antigen (HBsAg) responders. They met the primary efficacy study endpoint; the required amount of reduction in HBsAg from baseline.
- With the inarigivir 50mg monotherapy alone: only 1 of 14 patients was a HBsAg responder at week 12.
- With Vemlidy® alone: Only 3 of the 12 patients were HBsAg responders.
- The combination of inarigivir and Vemlidy®was generally safe and well-tolerated. No serious side events were observed over the 12-week treatment period, and the side effects attributed to the treatment were mild to moderate.